-
Chemical found to inhibit anthrax germination
Seven different chemicals do the trick, but only one works inside mammalian cells
-
-
Drexel researchers develop rapid cantilever biosensor
Technology has applications from E. coli and anthrax to prostate cancer
-
-
Argonne researchers corral E. coli
Unlike traditional centrifuging techniques, the new approach allows selective concentration of healthy cells
-
-
Intralytix seeks FDA approval of E. coli spray
Intended to control pathogens in food processing and medical setting, technique relies on microphages to immobilize bacteria
-
-
MedImmune accepts $15.6 billion buy-out offer
AstraZeneca outbids Merck and others to get its hands on the FluMist vaccine
-
-
TB victim receives TV
Facing a life of civil commitment, Russian-born Arizonan earns his creature comforts
-
-
General Dynamics Canada wins Canadian bio-sensor contract
After six years of succesful naval deployments, government will buy CAN$30 million worth of GDC’s VP Bio Sentry systems
-
-
Biotech industry set to break flu vaccine production record
Officials say industry will produce 132 million doses, with both Sanofi and MedImmune ramping up production capacity
-
-
FDA approves first bird flu vaccine
Government has been stockpiling Sanofi Pasteur’s vaccine for some time, but now it can be distributed without signed consent; concerns remain about efficacy
-
-
Digital angel buys Chemring's McMurdo
$7.5 million deal expected to pay dividends in 2009 when COSPAS-SARSAT equipment is replaced
-
-
NIH awards $23 million for six new influzena research centers
Federal government gets serious by expanding the Centers of Excellence for Influenza Research and Surveillance program
-
-
VaxGen tries to regroup
After HHS cancels its $877 million anthrax vaccine, company looks to merge or partner with others
-
-
Protein Sciences tests caterpillar-based flu vaccine
New approach to vaccine development relies on insect cells rather than bird eggs; method offers improved speed and safety
-
-
MedImmune to explore buy-out options
Board of directors reacts to heightened interest from Big Pharma and growing shareholder disatisfication
-
-
New technology turns A and B blood to O
A fresh approach to an old concept, ZymeQuest tests a machine capable of treating eight units in ninety minutes
-
The long view
Huge Areas May Face Possibly Fatal Heat Waves if Warming Continues
A new assessment warns that if Earth’s average temperature reaches 2 degrees C over the preindustrial average, widespread areas may become too hot during extreme heat events for many people to survive without artificial cooling.